Occam Places Ann Taylor as Board Member at Comanche Biopharma
Comanche is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has just appointed Ann Taylor to its Board of Directors.
Ann has an extraordinary record of achievement as a clinical development professional, with a distinguished career spanning Academia and Big Pharma. She most recently served as CMO of AstraZeneca and had previously spent a decade at Novartis leading portfolio management at NIBR, following two decades at Harvard and MassGen. She currently serves on the Boards of Terns Pharmaceuticals and Unlearn, a private company applying AI to clinical trials.
Ann has an MD from Harvard Medical School.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.